ABSTRACT
Objective To analyze and compare the chemical components of the volatile oil in different parts of Cryptotae-nia japonica .Methods Essential oils were extracted from the root ,stem ,leaf ,fruit of Cryptotaenia japonica through steam distillation .GC-MS analysis combined with Kovats retention index methods were used to analyze its main components .Results 28 peaks were separated and 28 compounds were identified from volatile oils from the root of Cryptotaenia japonica ,ac-counting for 86.66% of the total ,27 peaks were separated and 27 compounds were identified from volatile oils from stem of Cryptotaenia japonica ,accounting for 88 .01% of the total ,27 peaks were separated and 27 compounds were identified from volatile oils from leaves of Cryptotaenia japonica ,accounting for 94 .03% of the total ,26 peaks were separated and 26 com-pounds were identified from volatile oils from fruit of Cryptotaenia japonica ,accounting for 88 .32% of the total .35 kinds of volatile compounds were identified from the whole strain ,and the main components of each part of the volatile oil were sesquit-erpene compounds ,containing a small amount of monoterpenes .Among all the 35 compounds ,different parts of Cryptotaenia japonica share 22 compounds .Compounds 19 ,23 only exists in the volatile oil from the roots .Aromadendrene ,compound 25 , red myrrh alcohol only exists in the volatile oil from the fruit .So there is a certain difference in the types and quantity of the compounds .Conclusion The volatile oil of Cryptotaenia japonica contains many physiologically active substance .Take the whole plant as a medicine has its rationality ,which provide a scientific basis for the further research and development of Cryp-totaenia j aponica .
ABSTRACT
Aim To establish a mouse breast cancer model stab-ly expressing HER2. Methods 4T1-Luc mouse breast cancer cell line was transfected with the full-length human HER2 gene and selected with G418. The HER2 expression in 4T1-Luc stable cells was detected by fluorescence-activated cell sorting ( FACS) and Western blot. 4T1-Luc/HER2 cells were implanted into the mammary fat pads of BALB/c or nude mice. After tumor stabili-zation, mice were randomly assigned into 4 groups for treatment with PBS control, chA21, Trastuzumab, or chA21 plus Trastu-zumab. Tumor volumes were measured and tumor growth inhibi-tion ratios were calculated twice a week. At the end of experi-ment, tumor metastasis in mice was detected by bioluminescence imaging technology. Results Several 4T1-Luc/HER2 stable cell clones were obtained after G418 selection. FACS and West-ern blot analysis showed that all clones expressed HER2 protein at high levels. These 4T1-Luc/HER2 clones showed good tumor-igenicity in mice with steady tumor growth after one week of cell implantation. After 2-3 weeks, metastatic tumor cells were seen in the lung, cheek and groin areas. In BALB/c mice, the tumor growth inhibition ratio was 43. 3% in chA21 plus Trastuzumab group (P<0. 05 vs PBS control), which was higher than chA21 group (11. 1%) or Trastuzumab group (23%). In addition, the luminescence number and density of tumor metastases in lungs were significantly reduced in the antibody combination group. Conclusions The mouse model of spontaneously metastasizing breast cancer with HER2 overexpression is successfully estab-lished. The preliminary study suggests that anti-HER2 antibody combination of chA21 and Trastuzumab has excellent inhibitory effects on tumor growth and metastasis.